Table 3. Clinicopathological parameters of the study cohorts.
| screening | validation | serum cohort | |||
|---|---|---|---|---|---|
| ccRCC | CTRL | ccRCC | CTRL | ||
| n = 18 (%) | n = 118 (%) | n = 74 (%) | n = 30 (%) | n = 15% | |
| Sex | |||||
| male | 13 (82.2) | 81 (68.6) | 52 (70.3) | 18 (60.0) | 7 (46.7) |
| female | 5 (27.8) | 73 (31.4) | 22 (29.7) | 12 (40.0) | 8 (53.3) |
| Age | |||||
| mean | 62.3 | 65.5 | 63.3 | 63.2 | 59.9 |
| min-max | 43–81 | 36–89 | 35–89 | 42–82 | 41–79 |
| Pathological stage | |||||
| pT1 | 9 (50.0) | 68 (57.6) | n.a. | 15 (50.0) | n.a. |
| pT2 | 1 (5.6) | 10 (8.5) | n.a. | 0 (0) | n.a. |
| pT3 | 7 (38.9) | 37 (31.4) | n.a. | 15 (50.0) | n.a. |
| pT4 | 1 (5.6) | 3 (2.5) | n.a. | 0 (0) | n.a. |
| lymph node metastasis | 0 (0) | 4 (3.4) | n.a. | 1 (3.3) | n.a. |
| distant metastasis | 1 (5.6) | 17 (14.4) | n.a. | 1 (3.3) | n.a. |
| Fuhrman Grading | |||||
| grade 1 | 3 (16.7) | 12 (10.2) | n.a. | 1 (3.3) | n.a. |
| grade 2 | 13 (72.2) | 81 (68.6) | n.a. | 25 (83.3) | n.a. |
| grade 3 | 2 (11.1) | 19 (16.1) | n.a. | 4 (13.3) | n.a. |
| grade 4 | 0 (0) | 6 (5.1) | n.a. | 0 (0) | n.a. |
n.a., not applicable.